posted on December 16, 2014
Two MSI Principal Investigators, Associate Professor Reuben Harris (Biochemistry, Molecular Biology, and Biophysics) and Assistant Professor Daniel Harki (Medicinal Chemistry), have founded a start-up company that will create drug therapies for cancer treatment. ApoGen Biotechnologies, Inc. is developing a new class of drugs based on blocking the activity of the protein APOBEC, which is found in many cancer tumors. Both Professors Harris and Harki use MSI to support their research into APOBEC-family proteins.
An article about ApoGen Biotechnologies appeared recently on the OVPR’s Inquiry blog.